Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the experimental Alzheimer's treatment to market, despite promising clinical trial ...

Eli Lilly's stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer's disease. The FDA's Advisory Committee endorsed donanemab for ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...

A panel of independent advisors to the FDA recommended Eli Lilly's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If approved ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

Australia’s Therapeutic Goods Administration has approved a drug called donanemab for people in the early stages of Alzheimer ...

Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted ...

Lending support to his choice, Rocket Companies, on May 8, posted better-than-expected quarterly sales. Markets expect rate ...

Donanemab (Kisunla) is the first new drug approved in Australia for the treatment of mild cognitive impairment in 25 years.

Donanemab, made by Indianapolis-based Eli Lilly, works by helping the body remove amyloid plaque buildup in the brain, a hallmark of Alzheimer’s disease. Lilly said it will be sold under the ...